#Diagnostics #Medical devices
- In vitro diagnosis
- Liquid biopsy
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.Discover >
Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
#Diagnostics #Medical devices
Floating Genes develops diagnostic tools for use in liquid biopsies via the highly sensitive NGS detection of circulating tumor DNA.
In 2020, Dr. Dipanwita Biswas conceptualized a method to detect rare mutations in liquid biopsies, validated it in Genopole’s Shaker program and, in October 2021, founded Floating Genes.
Description of the Products / Services / Technology
The start-up is developing tools for the early detection of cancer in liquid biopsies. The initial approach comprises two principal components: a kit with “Enhance-seq” technology reagents, and a computer program to analyze next-generation sequencing data.
Customer references / Partnerships / Highlights
The project was chosen for Genopole’s Shaker program where its proof of concept was achieved. The project demonstrated its feasibility in a synthetic system. A Wilco and Réseau Entreprendre laureate, Floating Genes was selected then accredited by the Cancer Campus’s OncoEntrepreneur program at the OncoSTART and IFODS conference and by the EIT Health WildCard program.
Floating Genes is looking for scientific and clinical partnerships with, e.g., hospitals and biobanks (liquid biopsy samples) and experts in genetics and microfluidics.
2 staff members
Ultra-sensitive technology for the detection of rare mutations.
A low sequencing depth is sufficient for the technology.
In the same field
CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.Discover
Research & development for an in vitro diagnostic tool for endometriosisDiscover
SafeInsight seeks to provide a response to the growing concerns of consumers for the composition of the products they buy and accompanies manufacturers aiming to attentively circumscribe the problem of endocrine disruptors.Discover
Ciclix is a tech driven company specialized in process digitization for hospitals and focused on creating natural and efficient solutions for a variety of user profiles in the hospital environment.Discover
Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.Discover
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.Discover
Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell DiseaseDiscover
IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.Discover
Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.Discover
AgenT is developing an unprecedented blood test to identify patients with Alzheimer's disease much earlier in disease course than current detection methods are able to do. The company also does drug repositioning research to identify compounds potentially active in the silent phase of Alzheimer's disease.Discover